» Articles » PMID: 2421751

The Cardiovascular Effects of Xamoterol, a Beta 1-adrenoceptor Partial Agonist, in Healthy Volunteers at Rest

Overview
Specialty Pharmacology
Date 1986 Mar 1
PMID 2421751
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The cardiovascular effects of three single intravenous doses of a beta 1-adrenoceptor partial agonist, xamoterol (0.025, 0.05 and 0.1 mg kg-1) and placebo were studied in six healthy volunteers at rest using a single-blind design. In addition to heart rate and blood pressure measurements, cardiac contractility was measured by means of M-mode echocardiography and systolic time intervals. Ambulatory 24 h Holter-monitoring of the electrocardiogram was performed. Plasma concentrations of xamoterol were measured. Compared to baseline, xamoterol (0.025 mg kg-1) increased heart rate (61 +/- 3-68 +/- 3 beats min-1, means and SEM) and systolic blood pressure (119 +/- 3-138 +/- 5 mm Hg) but decreased pre-ejection period (100 +/- 4-76 +/- 5 msec). Stroke volume (88 +/- 6-104 +/- 10 ml), cardiac output (4.8 +/- 0.4-6.6 +/- 0.61 min-1), velocity of circumferential fibre shortening (1.15 +/- 0.06-1.50 +/- 0.06 circ s-1) were increased by xamoterol. No significant changes were produced by placebo. No dose-dependent effects were seen and maximum effects were produced by 0.025 mg kg-1 xamoterol. Significant effects were observed for 2 h. The areas under the plasma concentration curves (AUC0-12) showed a linear dose response. No adverse effects attributable to xamoterol were seen in haematological, biochemical, urinalysis or electrocardiographic tests. Four volunteers were aware of a more forceful heart beat after xamoterol, but this was mild and transient. It is concluded that xamoterol has a positive inotropic action.

Citing Articles

Lack of pharmacodynamic interactions between acute dose flosequinan and xamoterol. A pilot study in healthy subjects.

Ng H, Walley T, Tsao Y, Breckenridge A Eur J Clin Pharmacol. 1994; 46(4):361-5.

PMID: 7957523 DOI: 10.1007/BF00194406.


Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

FURLONG R, Brogden R Drugs. 1988; 36(4):455-74.

PMID: 2906865 DOI: 10.2165/00003495-198836040-00004.


Beta-adrenoceptor antagonists increase sinus arrhythmia, a vagotonic effect.

Bittiner S, Smith S Br J Clin Pharmacol. 1986; 22(6):691-5.

PMID: 2882771 PMC: 1401218. DOI: 10.1111/j.1365-2125.1986.tb02959.x.


Myocardial beta-adrenoceptor function and regulation in heart failure: implications for therapy.

Barnett D Br J Clin Pharmacol. 1989; 27(5):527-37.

PMID: 2547407 PMC: 1379917. DOI: 10.1111/j.1365-2125.1989.tb03414.x.


The pharmacokinetics of xamoterol in liver disease.

Nicholls D, Taggart A, McCann J, Bastain W, Shanks R Br J Clin Pharmacol. 1989; 28(6):718-21.

PMID: 2532923 PMC: 1380044. DOI: 10.1111/j.1365-2125.1989.tb03566.x.


References
1.
Teichholz L, KREULEN T, Herman M, Gorlin R . Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol. 1976; 37(1):7-11. DOI: 10.1016/0002-9149(76)90491-4. View

2.
Pombo J, Troy B, Russell Jr R . Left ventricular volumes and ejection fraction by echocardiography. Circulation. 1971; 43(4):480-90. DOI: 10.1161/01.cir.43.4.480. View

3.
Johnson B, Meeran M, Frank A, Taylor S . Systolic time intervals in measurement of inotropic response to drugs. Br Heart J. 1981; 46(5):513-21. PMC: 482689. DOI: 10.1136/hrt.46.5.513. View

4.
Felner J, Blumenstein B, SCHLANT R, Carter A, Alimurung B, Johnson M . Sources of variability in echocardiographic measurements. Am J Cardiol. 1980; 45(5):995-1004. DOI: 10.1016/0002-9149(80)90168-x. View

5.
Cohen H, Dcruz I, Arbel E, LANGENDORF R, Pick A . Tachycardia and bradycardia-dependent bundle branch block alternans: clinical observations. Circulation. 1977; 55(2):242-6. DOI: 10.1161/01.cir.55.2.242. View